Accessibility Menu
iSpecimen logo

iSpecimen(NASDAQ) ISPC

Current Price$2.06
Market Cap$3.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-96%
1 Month-26%
iSpecimen last closing stock price
MetricPriceDate
Last closeUSD 1.972026-07-24
iSpecimen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.19%USD 2.102026-07-17
1 month-26.49%USD 2.682026-06-24
3 month-62.23%USD 5.222026-04-24
Year to date-81.06%USD 10.402025-12-31
1 year-95.52%USD 44.002025-07-24
3 year-99.82%USD 1,088.002023-07-25
5 year-99.95%USD 4,168.002021-07-23
Since inception-99.97%USD 5,720.002021-06-17

iSpecimen Financials at a Glance

Market Cap

$3.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.03M

Net Income (TTM)

-$11.10M

EPS (TTM)

-$66.08

P/E Ratio

-0.03

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$2.06

Volume

43,052.006

Open

$2.07

Previous Close

$1.97

Daily Range

$1.97 - $2.08

52-Week Range

$1.93 - $127.20

Estimated Earnings Date

Aug 4, 2026

ISPC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About iSpecimen

iSpecimen helps researchers find human samples for medical studies. Its online platform connects hospitals and labs with scientists needing blood, tissue, or cells. This service supports drug development and disease research by making specimen sourcing easier.

Marketplace Magic: What iSpecimen Sells

  • Biospecimens: Human blood, tissue, and living cells for research; the company's reportable segment is biospecimens; used by drug and diagnostic companies.
  • Sequenced Data: Genetic data linked to tissue samples, available for purchase or subscription; supports advanced research projects.
  • Online Marketplace: Cloud-based platform for searching, quoting, and ordering specimens; used by research organizations worldwide.
  • Compliance Tools: Administrative features for managing legal and ethical requirements in specimen handling; helps both suppliers and buyers.
  • Supply Chain Services: Logistics and coordination for specimen delivery; ensures timely and compliant shipments.

Growth Spurts and Strategic Moves

  • Entered public markets with a 2021 IPO on NASDAQ.
  • Refreshed supplier network in 2024, ending 180 agreements to focus on quality.
  • Raised approximately $4 million in July 2025 and approximately $1.75 million in August 2025.
  • Expanded customer base to Europe, Middle East, Africa, and Asia Pacific by 2025.

Why iSpecimen Stands Out (Without Bragging)

iSpecimen’s just-in-time model reduces inventory risk by sourcing specimens only after orders are placed. Its platform integrates data from many hospitals and labs, making searches faster and more reliable. The company’s focus on automation and cost control has improved operational efficiency, even as revenue declined.

Five Things You Need to Know

  • Revenue was $713,135 in Q2 2025, down 75.1% from Q2 2024.
  • Net loss improved to $1.05 million in Q2 2025, down 50% year-over-year.
  • Specimen deliveries fell 57% year-over-year in Q2 2025 to 2,533 units.
  • Average selling price per specimen dropped 42% to $282 in Q2 2025.
  • Cash balance was $588,775 as of June 30, 2025, with negative working capital.

Bottom Line

iSpecimen has shifted its business model and cut costs to adapt to falling sales. The company’s platform remains central to connecting researchers with needed human samples worldwide.

AI Generated • Apr 16, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

7

CEO

Katharyn Mulcaire Field, MBA

Website

www.ispecimen.com

Headquarters

Woburn, MA 02420, US

ISPC Financials

Key Financial Metrics (TTM)

Gross Margin

-29.64%

Operating Margin

-961.36%

Net Income Margin

-1080.72%

Return on Equity

-584.67%

Return on Capital

-267.44%

Return on Assets

-168.00%

Earnings Yield

-33.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.52M

Volume

43.05K

Avg. Volume

366.76K

Financials (TTM)

Gross Profit

-$304.52K

Operating Income

-$9.88M

EBITDA

-$9.70M

Operating Cash Flow

-$6.51M

Capital Expenditure

-$1.00M

Free Cash Flow

-$7.51M

Cash & ST Invst.

$2.82M

Total Debt

$254.99K

iSpecimen Performance Analysis

iSpecimen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 10,402,303-6.6%
20232023-12-31USD 9,928,184-4.6%
20242024-12-31USD 9,291,115-6.4%
20252025-12-31USD 1,928,998-79.2%
iSpecimen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-32.6%
Q32025-09-30-85.1%
Q42025-12-31-51.4%
Q12026-03-31201.4%
iSpecimen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -926.7812.9%
20232023-12-31USD -982.116.0%
20242024-12-31USD -703.26-28.4%
20252025-12-31USD -91.15-87.0%
iSpecimen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3082.0%
Q32025-09-30-14.3%
Q42025-12-31-22.9%
Q12026-03-31-1028.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$156.01K

-85.2%

Gross Profit

$71.60K

-82.1%

Gross Margin

45.89%

N/A

Market Cap

$3.00MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$428.43K

N/A

Employees

7

N/A

Net Income

-$2.28M

-37.2%

EBITDA

-$2.14M

-77.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.82M

+260.2%

Total Debt

$254.99K

-15.0%

Accounts Receivable

$132.85K

-77.2%

Inventory

$0.00

N/A

Long Term Debt

$195.96K

-23.2%

Short Term Debt

$59.03K

+30.7%

Return on Assets

-1.68%

N/A

Return on Invested Capital

-9.78%

N/A

Free Cash Flow

-$3.36M

-206.8%

Operating Cash Flow

-$3.36M

-206.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BIAFbioAffinity Technologies, Inc.
$0.67+2.26%
NDRAENDRA Life Sciences Inc.
$4.94+1.54%
GLMDGalmed Pharmaceuticals Ltd.
$0.52+2.01%
SHPHShuttle Pharmaceuticals Holdings, Inc.
$2.88-0.35%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.24+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.20-0.03%
AALAmerican Airlines Group
$14.59+0.01%
FFord Motor Company
$14.46+0.01%

Questions About ISPC

What is the current price of iSpecimen?

iSpecimen is trading at $1.99 per share.

What is the 52-week range for iSpecimen?

Over the past 52 weeks, iSpecimen has traded between $1.93 and $127.20.

How much debt does iSpecimen have?

As of the most recent reporting period, iSpecimen reported total debt of $254.99K.

How much cash does iSpecimen have on hand?

iSpecimen reported $2.82M in cash and cash equivalents in its most recent financial results.

What is iSpecimen’s dividend yield?

iSpecimen does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services